
    
      The human clinical trial will be designed as a longitudinal prospective study. A total of 24
      titanium implants with a modified SLA surface (BLT SLActiveÂ®, Institute Straumann AG, Basel,
      Switzerland) will be placed in the mandibular first molar. 12 for the control group and for
      the 12 test group.
    
  